Gene Prediction Tools Market Report Scope and Overview:

The Gene Prediction Tools Market was valued at USD 188.60 Million in 2025 and is projected to reach USD 1,026.26 Million by 2035, registering a CAGR of 18.46% from 2026 to 2035.

The Gene Prediction Tools Market is steadily reshaping genome analysis by moving researchers from manual annotation and rule-based gene finders toward AI-driven platforms that identify genes, regulatory elements and disease-relevant variants across rapidly growing sequence datasets. The market is characterized by explosive growth in sequencing output from population genomics and clinical programmes, rising use of deep learning and genomic foundation models for variant effect and gene function prediction, and expanding cloud-based bioinformatics pipelines that make advanced tools accessible to more laboratories. Significant growth is being witnessed in services, hybrid AI-driven methods and diagnostics development, considering that pharmaceutical companies, diagnostic developers and research institutions continue investing in accurate, scalable gene prediction to support precision medicine.

Google DeepMind introduced AlphaGenome in June 2025, an AI model that predicts how single DNA variants affect thousands of molecular properties across long stretches of the genome, including in non-coding regions, reflecting the industry's broader shift toward foundation models for gene and variant interpretation.

Gene Prediction Tools Market Trends:

• Rising use of genomic foundation models continues improving prediction of gene function and variant effects.

• Growing integration of long-read and RNA sequencing evidence continues raising the accuracy of empirical gene annotation.

• Expanding cloud-based bioinformatics pipelines continue making advanced gene prediction accessible to smaller laboratories.

• Increasing population genomics programmes continue generating large datasets that require automated annotation.

• Rising clinical whole-genome sequencing continues extending gene prediction tools into diagnostic interpretation workflows.

U.S. Gene Prediction Tools Market Outlook:

The U.S. Gene Prediction Tools Market was valued at approximately USD 69.23 Million in 2025 and is projected to reach approximately USD 350.26 Million by 2035, registering a CAGR of approximately 17.6% from 2026 to 2035.

Demand across the United States continued to be shaped by the country's leadership in genomics research, substantial NIH funding for programmes such as All of Us, and a dense ecosystem of sequencing companies, bioinformatics software developers and AI-driven drug discovery firms. Rising adoption of clinical whole-genome and exome sequencing in oncology, rare disease and hereditary cancer testing continued reinforcing the country's position as the largest national market. Growing investment in AI and cloud computing for life sciences added further layers of sustained domestic demand, with pharmaceutical companies and diagnostic developers increasingly prioritizing scalable gene prediction and variant interpretation platforms.

Tempus AI announced the development of its first whole-genome sequencing assay, xH, in January 2025, aimed at supporting personalized treatment decisions in hematological oncology through comprehensive genomic analysis, expanding the use of advanced gene and variant interpretation in American clinical practice.

Gene Prediction Tools Market Segment Analysis:

• By Type, Software segment dominated the Gene Prediction Tools Market in 2025 with 67% share; Services segment is the fastest growing segment with a CAGR of approximately 19.9%.

• By Method, Empirical Methods segment dominated the Gene Prediction Tools Market in 2025 with 64% share; Others segment, comprising hybrid and AI-driven approaches, is the fastest growing segment with a CAGR of approximately 21.3%.

• By Application, Drug Discovery & Development segment dominated the Gene Prediction Tools Market in 2025 with 66% share; Diagnostics Development segment is the fastest growing segment with a CAGR of approximately 20.4%.

• By End-use, Industrial segment dominated the Gene Prediction Tools Market in 2025 with 61% share; Academic & Research segment is the fastest growing segment with a CAGR of approximately 19.6%.

By Type: Software Leads, Services Grow Fastest

The Software segment dominated the Gene Prediction Tools Market in 2025, driven by widespread use of standalone gene finders, integrated genome analysis platforms, cloud-based annotation pipelines and AI-enabled tools that identify coding and non-coding regions and predict gene structure and function. Software platforms process large sequencing datasets far faster than manual approaches and integrate with sequencing instruments and laboratory information systems. Continuous algorithm innovation and user-friendly interfaces reinforced this segment's position as the largest contributor to total market revenue throughout the base year.

The Services segment is the fastest growing in the Gene Prediction Tools Market owing to rising demand for custom genome annotation, computational analysis, data interpretation and bioinformatics consulting from organizations that lack in-house expertise. Pharmaceutical and biotechnology companies increasingly outsource genomic analysis to specialized providers to identify drug targets and understand genetic factors in drug response. Growing complexity of multi-omics datasets is accelerating this segment's growth trajectory. Expanding clinical genomics programmes further support demand.

By Method: Empirical Methods Lead, Hybrid and AI-Driven Methods Grow Fastest

The Empirical Methods segment dominated the Gene Prediction Tools Market because evidence-based approaches that use RNA sequencing, expressed sequence tags, protein homology and known annotations deliver high accuracy and reliability. These methods are the standard for annotating well-studied genomes and are widely used in research and clinical settings. Growing availability of transcriptomic and long-read sequencing data reinforced this segment's dominant contribution to total market revenue throughout the base year.

The Others segment, which includes hybrid, comparative genomics and machine-learning-based approaches, is the fastest growing as deep learning and genomic foundation models combine sequence features with experimental evidence to predict genes and variant effects more accurately. Ab initio methods remain essential for newly sequenced genomes and non-model organisms where experimental evidence is limited, and benefit from greater computing power and cloud infrastructure. Rising AI investment in genomics continues attracting adoption of integrated prediction frameworks.

By Application: Drug Discovery & Development Leads, Diagnostics Development Grows Fastest

The Drug Discovery & Development segment dominated the Gene Prediction Tools Market because gene prediction tools are critical for identifying novel therapeutic targets, characterizing disease-associated genes, supporting biomarker discovery and guiding targeted therapy design. Pharmaceutical companies rely on accurate gene and variant annotation to understand disease biology and stratify patients. Continued investment in precision oncology, rare disease and genetic medicines reinforced this segment's dominant contribution to total market revenue throughout the base year.

The Diagnostics Development segment is the fastest growing due to rising demand for precision medicine, clinical whole-genome and exome sequencing and hereditary disease and cancer testing. Gene prediction and variant interpretation tools help developers design molecular diagnostics and identify clinically relevant genes and mutations. Growing regulatory support and payer coverage for genomic testing continue attracting investment in diagnostic applications. Expanding newborn and population screening programmes further accelerate demand.

By End-use: Industrial Dominates, Academic & Research Grows Fastest

The Industrial segment dominated the Gene Prediction Tools Market because pharmaceutical, biotechnology, agricultural biotechnology and bioinformatics companies use gene prediction tools for drug discovery, biomarker identification, crop and animal genomics and commercial product development. These organizations invest heavily in software licences, computing infrastructure and outsourced analysis. Growing use of synthetic biology and precision medicine reinforced this segment's dominant contribution to total market revenue throughout the base year.

The Academic & Research segment is the fastest growing as universities, government laboratories and research institutes lead large genome sequencing and annotation projects, develop new algorithms and publish findings that drive wider adoption. Public funding for population genomics, biodiversity genomics and translational research continues expanding academic demand. Growing availability of open-source and cloud-based tools further supports adoption in research settings.

Regional Analysis:

North America Gene Prediction Tools Market Insights

North America dominated the Gene Prediction Tools Market with the largest revenue share of approximately 41.2% in 2025. Strong genomics research infrastructure, substantial NIH and private funding, comprehensive genomic databases and biobanks, and the presence of leading sequencing, bioinformatics and AI companies continued reinforcing this dominant regional position. The region was an early adopter of AI-driven gene and variant prediction tools across research and clinical settings. Growing precision medicine initiatives further reinforced this region's leadership position.

The United States accounted for the substantial majority of regional revenue, anchored by large-scale genomics programmes, clinical sequencing adoption and strong biopharma R&D. Canada added further demand through genomics research networks such as Genome Canada, and that combined strength kept the region the largest addressable market for gene prediction tools through the forecast period. Continued investment in AI for life sciences reinforced sustained demand.

Europe Gene Prediction Tools Market Insights

Europe held a meaningful share of global revenue, supported by a strong network of universities, research institutes and biotechnology firms, and substantial public funding through Horizon Europe and national genomics programmes. The European Bioinformatics Institute and national genome initiatives provide major data resources and annotation infrastructure. Growing integration of genomics into healthcare systems continued expanding demand. GDPR shapes how genomic data can be shared and analysed across borders.

The United Kingdom continued to lead demand at roughly 26.30% of European revenue, supported by Genomics England, UK Biobank and the Wellcome Sanger Institute. Germany and France contributed substantial additional demand through strong research infrastructure and national genomic medicine plans, and continued European investment in precision medicine should keep regional demand for gene prediction tools climbing through the forecast period. Additional demand from the Netherlands, Switzerland and the Nordic countries reinforced broader regional market strength.

Asia Pacific Gene Prediction Tools Market Insights

Asia Pacific is advancing at the fastest pace, growing at a CAGR of approximately 20.5% from 2026 to 2035. This growth is driven by rapidly expanding sequencing capacity in China, India, Japan, South Korea and Australia, government genomics initiatives, and diverse populations that offer rich opportunities for studying genetic variation, with new genome centres and bioinformatics companies continuing to broaden the region's addressable base well beyond its traditional smaller footprint. Growing biopharma R&D further supports adoption.

China held a substantial share of regional revenue, supported by large sequencing providers and national investment in biotechnology. Japan and India contributed meaningful additional demand, with Japan's precision medicine programmes and India's genome sequencing initiatives such as GenomeIndia both reinforcing the region's position as the fastest-growing market tracked in this report. Australia's Genomics Health Futures Mission and South Korea's national genome projects contributed further regional demand throughout the period.

MEA and Latin America Gene Prediction Tools Market Insights

The Middle East and Africa and Latin America both showed steady growth, driven by national genome programmes, rising healthcare investment and growing awareness of precision medicine across both areas. High rates of inherited disorders in some Middle Eastern populations increase the value of genomic analysis. International research collaborations continue supporting tool adoption in both regions.

Saudi Arabia led Middle East and Africa demand, supported by the Saudi Genome Program and investment under Vision 2030, while the UAE and Qatar contributed through national genome initiatives. In Latin America, Brazil accounted for the largest share of regional revenue, with its growing genomics research and agricultural biotechnology sectors continuing to anchor regional demand for gene prediction tools. Mexico and Argentina contributed additional demand through expanding research activity.

Market Dynamics:

Growth Drivers: Growing Genomic Data Volumes and Government Support for Genomics

The industry is driven by rapidly growing genomic data from next-generation and long-read sequencing, rising government and private investment in genomics research, the increasing prevalence of genetic disorders and cancer, and growing demand for personalized medicine. As research institutions and companies sequence more genomes, demand for accurate, automated gene prediction and annotation tools continues rising worldwide. National genomics programmes in Australia, India, the UK and the United States further reinforce this sustained industry-wide demand driver.

Rising adoption of artificial intelligence and machine learning continues reinforcing this driver, as deep learning models and genomic foundation models predict gene structure, regulatory elements and variant effects with greater accuracy. Growing cloud computing capacity continues making large-scale analysis more accessible, and that combination of data growth and AI innovation keeps demand rising at a steady, sustained pace. Expanding clinical genomics is further widening the addressable user base.

Restraints: High Costs and Shortage of Bioinformatics Expertise

The high cost of advanced genomic technologies, high-performance computing, specialized software and data storage continues posing a restraint on faster market-wide expansion, particularly for small laboratories and institutions in emerging economies. Software licensing, cloud computing and continuous upgrades add to operating costs. Budget constraints continue limiting adoption of the most advanced platforms.

A shortage of skilled bioinformatics professionals able to run tools and interpret complex results continues posing a further restraint. Variability in prediction accuracy across organisms and genomic regions, along with data privacy concerns for human genomic data, also slows adoption. Regulatory expectations for clinical-grade interpretation tools add further complexity.

Opportunities: Clinical Genomics Expansion and AI Foundation Models

Rising adoption of clinical genomics and genetic testing represents a significant opportunity, as hospitals and laboratories integrate whole-genome and exome sequencing into oncology, rare disease and hereditary cancer care. Vendors positioned early in accurate, validated gene and variant interpretation tools stand to capture meaningful share as clinical sequencing volumes grow. Expanding newborn and population screening programmes continue widening this addressable opportunity.

Advances in genomic foundation models and AI-driven prediction offer a second substantial opportunity, as these models open new ways to interpret non-coding variants and predict gene function across species. Providers that combine AI models, curated data and cloud delivery stand to capture meaningful share as research and drug discovery adopt AI-first workflows. Continued growth of genomics in Asia Pacific and the Middle East is further accelerating adoption.

Recent Developments:

• March 2025: The Australian Government announced an investment of about USD 500.1 million under the Genomics Health Futures Mission to strengthen genomic testing, improve disease diagnosis and support personalized treatment approaches.

• February 2025: Foundation Medicine announced plans to launch FoundationOne Germline and FoundationOne Germline More hereditary cancer tests in partnership with Fulgent Genetics, expanding access to germline genomic testing for hereditary cancer risk assessment.

• February 2025: The Arc Institute, with NVIDIA, released Evo 2, an open genomic foundation model trained on DNA from a broad range of species that can predict the functional impact of genetic mutations and support genome design.

Gene Prediction Tools Market key players are:

• Thermo Fisher Scientific Inc.

• Illumina, Inc.

• QIAGEN N.V.

• Danaher Corporation

• Bio-Techne Corporation

• Charles River Laboratories

• Eurofins Scientific

• GenScript Biotech

• MedGenome

• Sino Biological

• Syngene International

• Twist Bioscience

• Google DeepMind

• NVIDIA Corporation

• Tempus AI

• Foundation Medicine

• DNAnexus

Gene Prediction Tools Market Report Scope: